首页> 外文期刊>Experimental and clinical transplantation >Conversion of Calcineurin Inhibitors With Mammalian Target of Rapamycin Inhibitors After Kidney Transplant
【24h】

Conversion of Calcineurin Inhibitors With Mammalian Target of Rapamycin Inhibitors After Kidney Transplant

机译:肾移植后雷帕霉素抑制剂以哺乳动物为靶标的钙调磷酸酶抑制剂的转化

获取原文
       

摘要

One way to overcome chronic allograft nephropathy induced by calcineurin inhibitors in immunosuppression protocols for organ transplants is to replace such inhibitors with mammalian target of rapamycin inhibitors, which are not clinically nephrotoxic because they have better renal function. If patients tolerate replacement, there could be a clear preference for mammalian target of rapamycin inhibitors as a maintenance immunosuppressant after renal transplant. This replacement could be sufficient if it were used for a certain time after calcineurin inhibitors. This review considers the conversion effects of calcineurin inhibitors with mammalian target of rapamycin inhibitors from the view point of kidney function during different periods after a kidney transplant.
机译:克服钙调神经磷酸酶抑制剂在器官移植的免疫抑制方案中诱发的慢性同种异体移植肾病的一种方法是用哺乳动物靶标雷帕霉素抑制剂代替此类抑制剂,雷帕霉素抑制剂在临床上无肾毒性,因为它们具有更好的肾功能。如果患者能够耐受替代药物,那么显然可以优先选择雷帕霉素抑制剂的哺乳动物靶标作为肾脏移植后的维持性免疫抑制剂。如果在钙调神经磷酸酶抑制剂后使用了一定的时间,这种替代就足够了。本文从肾脏移植后不同时期的肾功能角度考虑钙调神经磷酸酶抑制剂与雷帕霉素抑制剂在哺乳动物中的转化作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号